Back to results
US 12,399,188 B2Granted
Biomarkers for cardiovascular events
AssigneeZora Biosciences Oy
InventorsMika Hilvo, Reijo Laaksonen
Life of this patent
Estimating the term…
Abstract
The present disclosure relates to methods and uses involving the determination of lipid concentrations in order to diagnose, predict, prevent and/or treat one or more cardiovascular events in a subject. The methods include analyzing lipid concentrations of a sample from the subject and comparing them to a control.
Claims17
A method for treating a subject being at risk to develop one or more cardiovascular (CV) events, wherein the method comprises:
- (a) assaying a sample from the subject to determine a concentration of at least one ceramide (Cer) selected from Cer(d18:1/16:0), Cer(d18:1/18:0), Cer(d18:1/24:1) or Cer(d18:1/24:0);
- (b) assaying the sample from the subject to determine a concentration of at least one phosphatidylcholine (PC), wherein the at least one PC comprises PC 14:0/22:6;
- (c) identifying the subject at risk to develop one or more CV events based on an increased concentration of the at least one Cer selected from Cer(d18:1/16:0), Cer(d18:1/18:0), or Cer(d18:1/24:1), when compared to a control, and/or a decreased concentration of the at least one Cer, when compared to a control, wherein the at least one Cer comprises Cer(d18:1/24:0), and
- a decreased concentration of PC 14:0/22:6, when compared to a control;
- and
- (d) treating the subject being at risk of developing one or more CV events, wherein the treating comprises administering an HMG-CoA reductase inhibitor.
3 more elements
Dependencies are inferred from the claim text.